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 学位論文の要旨 Abstract of Thesis 
Cancer is a leading cause of death in worldwide, accounting for an estimated 9.6 million deaths in 
2018，about 1 in 6 deaths is due to cancer. The most common cancers are: Lung (2.09 million cases), 
Breast (2.09 million cases), Colorectal (1.80 million cases), Prostate (1.28 million cases), Skin cancer 
(non-melanoma) (1.04 million cases) and Stomach (1.03 million cases). Meanwhile, the most common 
causes of cancer death are cancers of: Lung (1.76 million deaths), Colorectal (862, 000 deaths), Stomach 
(783, 000 deaths), Liver (782, 000 deaths) and Breast (627, 000 deaths). Approximately 70% of deaths 
from cancer occur in low- and middle-income countries. The economic impact of cancer is significant 
and is increasing. Therefore, each year billions of funds are allocated towards the research and 
development of new therapeutic strategies to combat this growing menace. With the advent of new 
scientific technologies and advancement in molecular cancer research, the future does seem promising. 
Nevertheless, considerable measures need to be taken in order to solve key issues revolving around this 
disease such as late presentation of symptoms, development of resistance to available treatments and 
lack of awareness.  
Targeted cancer therapies are drugs or other substances that block the growth and spread of cancer 
by interfering with specific molecules ("molecular targets") that are involved in the 
growth, progression, and spread of cancer. Many different targeted therapies have been approved for 
use in cancer treatment. These therapies include hormone therapies, signal transduction inhibitors, gene 
expression modulators, apoptosis inducers, angiogenesis inhibitors, immunotherapies and toxin 
delivery molecules. They have improved the disease outcomes in many cancer types but still the most 
serious challenge often encountered in cancer therapy is the development of drug resistance. It is 
believed that this acquisition of resistance is typically caused by small population of cells in tumor with 
pre-existing alterations, which can drive the resistance. Since the concept of Cancer stem cells (CSC) 
has been introduced in late 1990s, its importance in cancer research and development of novel anti-
cancer therapies is widely accepted. CSC which are also known as ‘tumor initiating cells’ represent very 
small population of tumor sharing common properties with normal stem cells. They are unique cells 
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with self-renewing and tumorigenic potential. Current radio and chemotherapies are able to eliminate 
the bulk of cancer cells but not cancer stem cells since they are endowed with specific resistance 
mechanisms. They give rise to new tumors and metastases leading to relapse of the disease. The 
recurring tumors are more malignant, prone to faster metastasis and exhibits enhanced drug resistance. 
Overall, this leads to therapy failure reducing the survival rate of cancer patients with specific resistance 
mechanisms. They give rise to new tumors and metastases leading to relapse of the disease. The 
recurring tumors are more malignant, prone to faster metastasis and exhibits enhanced drug resistance. 
Overall, this leads to therapy failure reducing the survival rate of cancer patients.  
We established a model of CSCs by culturing mouse induced pluripotent stem cells (miPSCs) in 
the presence of conditioned medium (CM) of Lewis Lung Carcinoma (LLC) cells. Base on this 
methodology of developing CSCs from miPSCs, we assessed the risk of carcinogenesis of 110 non-
mutagenic chemical compounds, most of which were known as inhibitors of cytoplasmic signaling 
pathways. We treated miPSCs with each compound for one week in the presence of the CM of LLC 
cells, while one week was too short for the CM to convert miPSCs into CSCs. As the result, miPSCs 
treated with PD0325901, CHIR99021 and Dasatinib respectively were found to survive and keep 
growing while the non-treated miPSCs differentiated and slowed their growth. The survived cells after 
the treatment exhibited the expression of stemness markers and the spheroid formation in suspension 
culture indicating that the stemness and the self-renewal capacity were significantly maintained for a 
week. When the cells were subcutaneously transplanted into Balb/c nude mice, they formed tumors, 
which were histopathologically diagnosed malignant. Collectively, we found the three signal inhibitors 
accelerated the conversion of miPSCs into CSCs. The expression levels of PI3K related genes were 
assessed and the expression of pi3kca was found extensively enhanced 10 to 30 folds of that in miPSCs. 
Simultaneously, pik3r5 and pik3r1 genes were moderately upregulated. These indicated PI3K in either 
class IA or IB should be enhancing the responsible signaling pathway. Consistently, AKT 
phosphorylation was found upregulated in the obtained CSCs. Since mTOR expression was recognized 
in all cells assessed in the experiments, survival of the converted cells might be explained by the 
sustained pluripotency, which was secured by the expression of stemness markers. Although the 
mechanism is not clear, inhibition of ErK1/2, tyrosine kinase and/or GSK-3β should closely be involved 
in the enhancement of PI3K-AKT-mTOR signaling pathway in undifferentiated cells resulting in the 
sustained stemness, which should lead the conversion into CSCs.  
 
 
 
 
